Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states: Current practices and outcome agreement between Belgium, the Netherlands and France

European Journal of Clinical Pharmacology

Volumn 69, Issue 12, 2013, Pages 2037-2043

  Van Wilder, P B ^a   Bormans, V V ^b   Dupont, A G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b SMART and BI   (Belgium)

Author keywords

Assessment; Pharmaceutical product; REA; Reimbursement; Relative effectiveness

Indexed keywords

BOSENTAN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; IMMUNOMODULATING AGENT; IVABRADINE; NEW DRUG; ORPHAN DRUG; RANIBIZUMAB; SAXAGLIPTIN; SORAFENIB; TEMSIROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VILDAGLIPTIN;

ARTICLE; BELGIUM; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MANUFACTURE; EUROPEAN UNION; EVIDENCE BASED MEDICINE; FRANCE; HUMAN; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT;

BELGIUM; DRUG THERAPY; EUROPEAN UNION; FRANCE; HUMANS; NETHERLANDS; REIMBURSEMENT MECHANISMS; TREATMENT OUTCOME;

EID: 84892374588     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1577-6     Document Type: Article

References (25)

1. The European Parliament and the Council of the European Union (2004) Regulation (EC) No 726/2004. Offic J Eur Union L136:1-33
2. European Council (1989) Transparency Dir. 89/105/EEC. Offic J Eur Union L40:65-71
3. Eichler HG, Bloechl-Daum B, Abadie E et al (2010) Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discovery 9:277-291
4. Kleijnen S, George E, Goulden S et al (2012) Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. Value Health 15:954-960. doi:10.1016/jval.2012.04.10
5. le Polain M, Franken M, Koopmanschap M et al. (2013) Drug reimbursement systems: international comparison and policy recommendations. KCE Reports 147C 2011. Available at: https://kce.fgov. be/publication/report/drug-reimbursement- systems-internationalcomparison-and-policy-recommendations-0. Accessed 8 May 2013
6. European Pharmaceutical Forum (2013) Final conclusions and recommendations of the pharmaceutical forum, 2008. Available at: http://ec. europa.eu/enterprise/sectors/healthcare/files/docs/pharmaforum-final- conclusions-brochure-en.pdf. Accessed 8 May 2013
7. European Network on Health Technology Assessment (EUnet HTA) (2013) Joint Action 2, 2012-15. Work Package 5. HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals. Available at: http://www.eunethta. eu/sites/5026.fedimbo.belgium.be/files/ Model%20for%20Rapid%20REA%20of%20pharmaceuticals-final-20130311-reduced.pdf. Accessed 8 May 2013
8. D'Andon A (2011) Assessment of pharmaceuticals in France: actual benefit and therapeutic added value. In: Drug Information Association 23rd Annual Euro Meeting. Drug Information Association, Geneva
9. Landis J, Koch G (1977) Themeasurement of observer agreement for categorical data. Biometrics 33(1):159-174
10. College voor Zorgverzekeringen (2013) Stand van de Wetenschap en de Praktijk. Available at: http://www.cvz.nl/binaries/live/cvzinternet/hst-content/ nl/documenten/rapporten/2007/rpt0711+stand+ wetenschap+en+praktijk.pdf. Accessed 8 May 2013
11. College voor Zorgverzekeringen (2013) Procedure beoordeling extramurale geneesmiddelen. Available at: http://www.cvz.nl/binaries/live/cvzinternet/hst- content/nl/documenten/rubriek+zorgpakket/cfh/procedure-beoordeling-extramurale- geneesmiddelen.pdf. Accessed 8 May 2013
12. RIZIV (2013) Template for pharmaceutical reimbursement submission. Available at: https://www.riziv.fgov.be/inami-prd/SSP/DEM2/Pdf/GuideClass1nl. pdf. Accessed 8May 2013
13. Zentner A, Velasco-Garrido M, Busse R (2013) Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. GMS Health Technology Assessment, vol. 1, 2005. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011319/pdf/HTA- 01-09. pdf. Accessed 8 May 2013
14. Annemans L, Cleemput I, Hulstaert F et al (2011) Valorising and creating access to innovativemedicines in the European Union. Front Pharmacol 2(57):1-6
15. Meyer F (2013) Rencontres HAS 2011-L'heure d'une collaboration européenne pour l'évaluation en vue du remboursement est-elle venue? Available at: http://www.has-sante.fr/portail/upload/docs/application/ pdf/2011-12/tr1-itw-vvd05-12-11.pdf. Accessed 8 May 2013
16. Charles River Associates (2013) A comparative analysis of the role and impact of health technology assessment, 2011. Available at: http://www.efpia.eu/ sites/www.efpia.eu/files/HTA%20Comparison% 20Report%20Updated%20July%2026%202011%20STC.pdf. Accessed 8 May 2013
17. Van Wilder PB, Dupont AG (2009) Reimbursement of medicines in Belgium: role of evidence-based medicine. Acta Clin Belg 64(2): 120-127
18. Van Wilder P, Dupont A (2008) Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome? Value Health 11(4):784-787
19. Haute Autorité de Santé. Rapport annuel d'activité 2009. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/ 2011-02/has-rapport-activite-2009-2011-02-25-11-31-57-229.pdf. Accessed 8 May 2013
20. Kanavos P, Nicod E, van den Aardweg S et al (2010) The impact of health technology assessments: an international comparison. Euro Observer 12(4):1-7
21. Jönsson B (2011) Relative effectiveness and the European pharmaceutical market. Eur J Health Econ 12:97-102
22. European Federation of Pharmaceutical Industries and Associations. Average time intervals between marketing authorization and patient access for EMEA medicines. Patients W.A.I.T. Indicator-2010 Report. Available at: http://www.efpia.eu/sites/www.efpia.eu/files/WAIT-Indicator-Report-2010- Executive-Summary-20100629-002-EN-v1.pdf. Accessed 8 May 2013
23. van Luijn J, Gribnau F, Leufkens H (2006) Availability of comparative trials for the assessment of newmedicines in the European Union at the moment of market authorization. Br J Clin Pharmacol 63:159-162
24. Naci H, Cylus J, Vandoros S et al (2012) Raising the bar for market authorisation of new drugs. BMJ 344:e4261. doi:10.1136/bmj.e4261
25. Eaton J, Hubbard C, Hawkins N (2011) A review of the NICE appeals process. In: 14th ISPOR European Congress. Madrid